Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NKG2D CAR-T Cell Therapy for Relapsed/Refractory AML
NCT04658004Phase 1Not yet recruiting
- Sponsor
- Zhejiang University
- Start
- Jan 2021
- Primary completion
- Jan 2024
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of NKG2D CAR T cells in acute myeloid leukemia (AML), sponsored by Zhejiang University. Primary endpoints: Dose-limiting toxicity at 28 days and Treatment-emergent adverse events at 2 years. Planned start Jan 2021; status: not yet recruiting.
02
Drugs
NKG2D CAR T cells
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT04658004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04658004.